Table 8.

Results from generalized linear models estimated by generalized estimating equations predicting the progression from MCI to Alzheimer’s disease (AD) dementia. All predictors in these models were added to the baseline predictors from Model 3A (Table 5). Hyperactivity and Mood symptoms were derived from the Neuropsychiatric Inventory Questionnaire. Models include the presence/absence of various medication classes, as well as whether participants received a new prescription for a cognition-enhancing medication since the previous study visit. Positive coefficients indicate that having a prescription for one or more of the medications was associated with a higher probability of progressing to AD dementia.

Analysis 6: Medications and Progression to AD dementia
Effect	B	95% CI	Wald Z	p	Exp(B)
Model 6A
Antidepressants	0.69	[0.36,1.03]	16.33	< .001	2.00
Model 6B
Antidepressants	0.48	[0.11,0.85]	6.50	.011	1.62
Hyperactivity	0.20	[0.08,0.32]	10.70	.001	1.22
Mood	0.25	[0.16,0.34]	27.87	< .001	1.28
Model 6C
Benzodiazepines	−0.16	[−0.85,0.53]	0.21	.648	0.85
Model 6D
Cognition Meds	1.01	[0.41,1.62]	10.73	.001	2.75
Model 6E
Cognition Meds	0.98	[0.26,1.70]	7.06	.008	2.67
Hyperactivity	0.20	[0.07,0.32]	9.75	.002	1.22
Mood	0.26	[0.17,0.35]	31.27	< .001	1.30
Model 6F
New Cog. Med	1.11	[0.46,1.76]	11.16	.001	3.03
Model 6G
New Cog. Med	1.15	[0.42,1.88]	9.62	.002	3.17
Hyperactivity	0.20	[0.08,0.32]	9.49	.002	1.22
Mood	0.26	[0.16,0.36]	32.23	< .001	1.30